Benzinga··Vandana SinghAbbVie Beats Q1 Expectations on Immunology, Neuroscience Surge
AbbVie exceeded Q1 earnings expectations with $15B revenue and raised 2026 guidance, driven by strong immunology and neuroscience portfolio performance.
ABBVrevenue beatguidance raise